New drug combo for large B-cell lymphoma before chemotherapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of three drugs—pola, zanubrutinib, and lenalidomide plus prednisone—for people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this treatment can control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma.
- You must be at least 18 years old.
- You must not have received any chemotherapy before.
- You must be willing to follow the study schedule and procedures.
- Your doctor expects you to live at least 3 months.
- You must not have serious infections or unstable heart, liver, kidney, or metabolic conditions.
- Pregnant or breastfeeding women cannot participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a new combination of three targeted drugs as the first treatment for aggressive B-cell lymphomas. The goal is to see if this approach can effectively treat the lymphoma and reduce the need for standard chemotherapy.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.